January 28, 2021 – Intalere Choice, the preferred portfolio subsidiary of Intalere, announced a new agreement with Xellia Pharmaceuticals USA.
Xellia Pharmaceuticals develops and produces a portfolio of quality, established and innovative injectable products for healthcare providers.
Through the agreement, Intalere members will receive negotiated pricing on generic pharmaceuticals and injectable anti-infectives for treatment against serious and often life-threatening infections.
This contract is currently effective through March 31, 2024.